The impact of smoking on immunological response to SARS-COV 2: a nationwide seroepidemiological study

Background Smoking influences cellular and humoral immune responses and affects the immune system by increasing inflammation and decreasing activity against infections. The current study investigates the association between smoking and immunological response to SARS-CoV-2 in the Armenian population....

Full description

Saved in:
Bibliographic Details
Published in:European journal of public health 2022-10, Vol.32 (Supplement_3)
Main Authors: Sahakyan, S, Musheghyan, L, Muradyan, D, Sargsyan, Z, Petrosyan, V, Khachadourian, V, Harutyunyan, A
Format: Article
Language:English
Subjects:
Antibodies
Chronic illnesses
COVID-19
Demographic variables
Demographics
Demography
Health care facilities
Immune response
Immune response (humoral)
Immune system
Immunology
Infections
Infectious diseases
Population studies
Public health
Random sampling
Regression analysis
Regression models
Risk
Risk factors
Sampling
Seroepidemiology
Severe acute respiratory syndrome coronavirus 2
Smoking
Statistical analysis
Statistical sampling
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Smoking influences cellular and humoral immune responses and affects the immune system by increasing inflammation and decreasing activity against infections. The current study investigates the association between smoking and immunological response to SARS-CoV-2 in the Armenian population. Methods We performed a nationwide cross-sectional seroepidemiological study among the adult population (≥18 years old) in Armenia. We used a multi-stage cluster random sampling to recruit participants from the capital city and all regions of Armenia. We invited selected participants to primary healthcare facilities to provide blood samples for antibody testing followed by a phone survey on demographic characteristics, smoking status, and other variables. Logistic regression analysis was used to test the relationship between smoking and having SARS-CoV-2 antibodies adjusted for other covariates. Results 3483 people participated in the study (71% women). The total sample included 16.8% current smokers (n = 571), 8.6% past smokers (n = 294) and 76.4% never smokers (n = 2538). The prevalence of SARS CoV-2 antibodies among current smokers was statistically significantly lower as compared with never smokers (46.9% vs 73.4%, p-value
ISSN:1101-1262
1464-360X
DOI:10.1093/eurpub/ckac131.143